The Cancer Institute of New Jersey (CINJ) is participating as one of 50 sites throughout the United States in a clinical trial known as COMET-2 that is investigating alternate methods of pain control for prostate cancer patients, according to a CINJ article posted on Newswise. The trial will examine if the drug Cabozantinib can reduce bone pain in people with metastasized prostate cancer that is not responsive to hormone therapy.
During the trial, researchers will compare patients who are taking Cabozantinib with those who are taking Mitoxantrone and Prednisone typically prescribed today.
Pain associated with bone metastases can be debilitating. Current therapies for the pain are not effective for everyone, spurring researchers to create the referenced national trial.
Adults who have castration-resistant prostate cancer, have bone scan evidence of the disease spreading to the bones and who undergo various other tests may be eligible to enter the clinical trial.
One can get more information on the trial by calling the Cancer Institute of New Jersey’s Office of Human Research Services at (732) 235-8675 or by emailing cinjclinicaltrials@umdnj.edu.
Improvements in cancer treatment can lead to both improved health and quality of life for those who have been diagnosed with the disease. However, a healthcare professional’s misdiagnosis, failure to diagnose, or delayed cancer diagnosis can prevent a patient from receiving the care he or she needs. If you believe your disease process was permitted to progress due to shortcomings in care provided by your healthcare providers, call 973-845-4421 to receive a no-cost consultation with a failure to diagnose cancer lawyer at Blume Forte. With decades of experience we may be able to provide you with a comprehensive understanding of your rights and potential options.